Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 16/20 | 0.70 |
| ▸ | SELP | P16109 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17148792 | 1.00 | SELE (0.70) | SELESELP | |
| SCHEMBL9613558 | 0.93 | SELE (0.75) | SELESELP | |
| SCHEMBL14217735 | 0.91 | SELE (0.74) | SELESELP | |
| SCHEMBL11962134 | 0.91 | SELE (0.74) | SELESELP | |
| SCHEMBL11981958 | 0.90 | SELE (0.79) | SELESELP | |
| SCHEMBL11962145 | 0.87 | SELE (0.73) | SELESELP | |
| SCHEMBL12257313 | 0.87 | SELE (0.72) | SELESELP | |
| SCHEMBL11982145 | 0.86 | SELE (0.81) | SELESELP | |
| SCHEMBL9613583 | 0.85 | SELE (0.68) | SELESELP | |
| SCHEMBL17151779 | 0.85 | SELE (0.56) | SELESELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284420-A1 | E-SELECTIN ANTAGONIST COMPOUNDS AND METHODS OF USE | GLYCOMIMETICS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284420-A1 | E-SELECTIN ANTAGONIST COMPOUNDS AND METHODS OF USE | SELE, SELPLG, SELP | SELE 1/4885SELP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.